Exchange: NYSE·Updated 07:58 PM EDT
News
all
press releases
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto
FDA approves Novartis' Pluvicto for earlier-stage metastatic prostate cancer, nearly doubling eligible patients.read more...
Benzinga
More News
ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut
Alnylam stock plunges after Q2 earnings and revenue miss estimates, while a cut to 2026 product sales guidance overshadows record quarterly Amvuttra sales.
Zacks
Novartis chart may soon 'complete a well-defined bullish reversal,' Cappelleri says
The Swiss drugmaker reported earnings a few days ago and, so far, has done a good job holding near its recent highs...
CNBC: Top News
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
Zacks
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?
INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.
Zacks
Company News for July 22, 2026
Companies in The News Are: NVS, GM, SYF, MMM
Zacks
Novartis (NVS) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Novartis CEO on 2Q Profit Beat, Investing in Pipeline
Novartis CEO on 2Q Profit Beat, Investing in Pipeline...
Bloomberg Markets and Finance-YouTube
Novartis CEO on Q2 earnings beat and patent expiries
Novartis CEO on Q2 earnings beat and patent expiries...
CNBC Television-YouTube
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win
Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
Zacks

Advertisement|Remove ads.